Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors

Expanding the US Food and Drug Administration–approved indications for immune checkpoint inhibitors in patients with cancer has resulted in therapeutic success and immune-related adverse events (irAEs). Neurologic irAEs (irAE-Ns) have an incidence of 1%–12% and a high fatality rate relative to other...

Descripción completa

Detalles Bibliográficos
Autores principales: Guidon, Amanda C, Burton, Leeann B, Chwalisz, Bart K, Hillis, James, Schaller, Teilo H, Amato, Anthony A, Betof Warner, Allison, Brastianos, Priscilla K, Cho, Tracey A, Clardy, Stacey L, Cohen, Justine V, Dietrich, Jorg, Dougan, Michael, Doughty, Christopher T, Dubey, Divyanshu, Gelfand, Jeffrey M, Guptill, Jeffrey T, Johnson, Douglas B, Juel, Vern C, Kadish, Robert, Kolb, Noah, LeBoeuf, Nicole R, Linnoila, Jenny, Mammen, Andrew L, Martinez-Lage, Maria, Mooradian, Meghan J, Naidoo, Jarushka, Neilan, Tomas G, Reardon, David A, Rubin, Krista M, Santomasso, Bianca D, Sullivan, Ryan J, Wang, Nancy, Woodman, Karin, Zubiri, Leyre, Louv, William C, Reynolds, Kerry L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291304/
https://www.ncbi.nlm.nih.gov/pubmed/34281989
http://dx.doi.org/10.1136/jitc-2021-002890

Ejemplares similares

Ejemplares similares